1.Pathogeny and treatment of 50 nasopharyngeal tuberculosis cases.
Yiluan JIAN ; Baoying LIU ; Lixia GUO ; Shaoyan KONG ; Xiaomin SU ; Chunli LU
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2012;26(24):1138-1140
OBJECTIVE:
To analyze the clinical characters and treatment of nasopharyngeal tuberculosis, and to provide a scientific basis for improving clinical diagnosis of nasopharyngeal tuberculosis.
METHOD:
The clinical materials of 50 patients diagnosed as nasopharyngeal tuberculosis in Guangzhou Chest Hospital were reviewed and analyzed. All the 50 patients were given regular antituberculosis treatment with 3HRZS(E)/9HR(E) for one year, and were treated through nasal spray with combination medication of isoniazid, rifampicin and streptomycin injection solution for 3 months.
RESULT:
All patients were cured through regular antituberculosis treatment for one year, and no recrudescence cases were found in 2 years of follow-up.
CONCLUSION
Nasopharyngeal tuberculosis is rare and the clinical manifestation is atypical. It is extremely easy to cause clinical misdiagnosis. A full understanding of the pathogenesis, timely clinical characters under nasopharyngoscope and histopathological examination results are the keys to diagnosis, and to giving regular antituberculosis treatment to obtain satisfactory curative effect.
Adolescent
;
Adult
;
Aged
;
Antitubercular Agents
;
therapeutic use
;
Female
;
Humans
;
Male
;
Middle Aged
;
Nasopharyngeal Diseases
;
diagnosis
;
drug therapy
;
microbiology
;
Tuberculosis
;
diagnosis
;
drug therapy
;
Young Adult
3.MLL4 Regulates the Progression of Non–Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis
Yang YANG ; Rongfang QIU ; Qiaoyou WENG ; Ziwei XU ; Jingjing SONG ; Siyu ZHAO ; Miaomiao MENG ; Dengke ZHANG ; Chunli KONG ; Hailin WANG ; Min XU ; Zhongwei ZHAO ; Jiansong JI
Cancer Research and Treatment 2023;55(3):778-803
Purpose:
Mixed-lineage leukemia protein 4 (MLL4/KMT2D) is a histone methyltransferase, and its mutation has been reported to be associated with a poor prognosis in many cancers, including lung cancer. We investigated the function of MLL4 in lung carcinogenesis.
Materials and Methods:
RNA sequencing (RNA-seq) in A549 cells transfected with control siRNA or MLL4 siRNA was performed. Also, we used EdU incorporation assay, colony formation assays, growth curve analysis, transwell invasion assays, immunohistochemical staining, and in vivo bioluminescence assay to investigate the function of MLL4 in lung carcinogenesis.
Results:
We found that MLL4 expression was downregulated in non–small cell lung cancer (NSCLC) tissues compared to adjacent normal tissues and tended to decrease with disease stage progression. We analyzed the transcriptomes in control and MLL4- deficient cells using high-throughput RNA deep sequencing (RNA-seq) and identified a cohort of target genes, such as SOX2, ATF1, FOXP4, PIK3IP1, SIRT4, TENT5B, and LFNG, some of which are related to proliferation and metastasis. Our results showed that low expression of MLL4 promotes NSCLC cell proliferation and metastasis and is required for the maintenance of NSCLC stem cell properties.
Conclusion
Our findings identify an important role of MLL4 in lung carcinogenesis through transcriptional regulation of PIK3IP1, affecting the PI3K/AKT/SOX2 axis, and suggest that MLL4 could be a potential prognostic indicator and target for NSCLC therapy.
4.Clinical study on 137 cases of unrelated single unit umbilical cord blood hematopoietic stem cell transplantation.
Hua ZHU ; Yi ZHANG ; Huanying JIN ; Yinting WANG ; Xiayan SHAO ; Jingsi KONG ; Wenhao HUANG ; Yan HONG ; Chunli LI ; Feng GAO ; Liang CHEN ; Feng WANG ; Yao LU
Chinese Journal of Hematology 2015;36(2):140-143
OBJECTIVETo evaluate relevant prognostic factors of unrelated single unit umbilical cord blood hematopoietic stem cell transplantation (sUCBT), and to explore the correlation between cryopreservation time of cord blood and cell viability and outcome of sUCBT.
METHODSRetrospective analysis of 137 patients undergoing sUCBT with cord blood provided by Shanghai Cord Blood Bank from Mar. 15, 2007 to Dec. 26, 2013 were performed in this study. The mean cryopreservation time of 137 units cord blood was 698(96-1968) days, with mean cell viability of 87.4% after thawing.
RESULTSNo statistical difference on cell viability, hematopoietic reconstitution, graft failure, acute graft versus host disease (GVHD) and overall survival (OS) was found between patients transfused with cord blood preserved below and above 2 years. The 5-year OS of patients transfused with cord blood preserved below and above 2 years were 55.6% and 67.9%, respectively (P=0.124). OS of the UCBT at 2011 and before, and after 2011 was 48.7% and 79.6%, respectively (P=0.001). Age above 16-year-old (RR=2.830, P=0.027) and UCBT at 2011 and before (RR=0.203, P<0.001) were two risk factors of treatment related mortality.
CONCLUSIONOutcome of sUCBT in China had significant improvement in recent 2 years. Cryopreservation time of cord blood had no statistical correlation to cell viability after thawing and clinical outcome.
Cell Survival ; China ; Cord Blood Stem Cell Transplantation ; Fetal Blood ; Graft vs Host Disease ; Hematopoietic Stem Cell Transplantation ; Humans ; Retrospective Studies
5.Impact of cryopreservation duration of 605 units umbilical cord blood on quality of hematopoietic stem cell and outcome of clinical transplantation.
Yi ZHANG ; Hua ZHU ; Huanying JIN ; Yinting WANG ; Xiayan SHAO ; Jingsi KONG ; Wenhao HUANG ; Yan HONG ; Chunli LI ; Feng GAO ; Liang CHEN ; Feng WANG ; Yao LU
Chinese Journal of Hematology 2015;36(1):1-3
OBJECTIVETo investigate the impact of cryopreservation duration of umbilical cord blood (UCB) on quality of hematopoietic stem cell and outcome of clinical transplantation.
METHODS605 units of UCB which had been used in clinical transplantation were previously cryopreserved for 820 (88-2651) days in average. UCB was detected for total nucleated cell count, CD34+ cells count, cell recovery rate, cell viability and CFU-GM after thawing.
RESULTSNo statistical correlation was found between cryopreservation duration and cell recovery rate, cell viability. CFU-GM decreased along with the extension of cryopreservation duration (P=0.011), ranging between 109.6 and 105.7/1 × 10⁵. There was no significant difference on hematopoietic reconstitution time, graft failure, acute GVHD and overall survival among groups with different cryopreservation duration.
CONCLUSIONCryopreservation duration has no significant effect on cell recovery rate, cell viability and clinical transplantation outcome. Extension of cryopreservation duration may reduce CFU-GM of stem cells with fluctaion still in normal range. UCB could maintain cell viability and function to achieve satisfactory clinical transplantation outcome even when thawed after 3 to 7 years' cryopreservation.
Cell Count ; Cell Survival ; Cryopreservation ; Fetal Blood ; Graft vs Host Disease ; Granulocyte-Macrophage Progenitor Cells ; Hematopoietic Stem Cell Transplantation ; Hematopoietic Stem Cells ; Humans ; Treatment Outcome